Allmed Solutions

Company Overview

Snapshot

Founded in January 2001, Allmed Solutions operates with 11–50 employees and has raised $3.4M across two funding rounds, with David Milch as an investor. The company went public on TASE in February 2007, marking a significant milestone in its journey to commercialize minimally invasive medical devices.

Business overview

Allmed Solutions develops, manufactures, and markets minimally invasive medical devices aimed at improving patient recovery. The company's product lines include embolic protection devices, urological and biliary stents, and pelvic organ prolapse repair devices. Allmed Solutions is also actively developing a gastro-duodenal sleeve for type 2 diabetes treatment and a mitral valve replacement. Operating within the Health Tech & Life Sciences sector, specifically Medical Devices, the company serves global markets including the United Arab Emirates and Egypt, focusing on hospitals and medical professionals.

Strategic signal

In May 2026, TruLeaf Medical, a fully-owned subsidiary of Allmed Solutions, successfully completed the second stage of valve implantation in two additional patients. This milestone, following the initial successful implantation of a first-of-its-kind heart valve via catheter in September 2025, signals significant progress in the company's mitral valve replacement technology. It validates the potential for less invasive cardiac procedures, positioning Allmed Solutions as an innovator in the cardiovascular medical device market and potentially expanding its addressable market by offering alternatives to open-heart surgeries.

Company Intelligence Q&A

What was a significant recent clinical achievement for Allmed Solutions?

In May 2026, TruLeaf Medical, a fully-owned subsidiary of Allmed Solutions, successfully completed the second stage of valve implantation in two additional patients, advancing its catheter-based heart valve technology.

What was a key development for TruLeaf Medical in September 2025?

In September 2025, Allmed Solutions' subsidiary, TruLeaf-Medical, announced the successful completion of stage 1 of implanting a first-of-its-kind heart valve via catheter, without surgery.

What was a notable financial event for Allmed Solutions in January 2023?

In January 2023, Allmed Solutions reported the receipt of full payment for a PIPE fundraising round, totaling over $3.5 million.

When did Allmed Solutions achieve a landmark in heart valve replacement?

In December 2025, Allmed Solutions achieved a landmark 'Needle-Stick' heart valve replacement, marking a dramatic success in a first-in-human trial.

What grant did TruLeaf Medical receive in August 2024?

In August 2024, TruLeaf Medical, a subsidiary of Allmed Solutions, was awarded an 11.5 million NIS grant by the Israel Innovation Authority.